Alternative links to fulltext:
| Item type: | Article | ||||
|---|---|---|---|---|---|
| Journal or Publication Title: | Archiv der Pharmazie | ||||
| Publisher: | Wiley | ||||
| Volume: | 328 | ||||
| Number of Issue or Book Chapter: | 5 | ||||
| Page Range: | pp. 457-463 | ||||
| Date: | 1995 | ||||
| Additional Information (public): | CAN 123:74226 1-3 Pharmacology 105855-87-6; 105856-21-1; 105856-22-2; 105856-23-3; 105928-14-1; 105990-36-1; 165289-81-6 Role: BAC (Biological activity or effector, except adverse), BPR (Biological process), BSU (Biological study, unclassified), PRP (Properties), THU (Therapeutic use), BIOL (Biological study), PROC (Process), USES (Uses) (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents); 10025-99-7; 111112-21-1 Role: RCT (Reactant), RACT (Reactant or reagent) (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) | ||||
| Institutions: | Chemistry and Pharmacy > Institute of Pharmacy > Alumni or Retired Professors > Prof. Schönenberger | ||||
| Projects (Historical): | SFB 234 | ||||
| Identification Number: |
| ||||
| Keywords: | Conformation and Conformers (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Estrogen receptors Role: BPR (Biological process), BSU (Biological study, unclassified), BIOL (Biological study), PROC (Process) (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) Estrogens Role: BSU (Biological study, unclassified), BIOL (Biological study) (redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Receptors Role: BPR (Biological process), BSU (Biological study, unclassified), BIOL (Biological study), PROC (Process) (estrogen, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) Molecular structure-biological activity relationship (estrogenic, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Neoplasm inhibitors (mammary gland, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Mammary gland (neoplasm, inhibitors, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) Molecular structure-biological activity relationship (neoplasm-inhibiting, redn. of estrogenic side effects of mammary tumor-inhibiting drug [(chlorohydroxyphenyl)ethylenediamine]chloroplatinum(II) by variation of ring substituents) phenylethyleneamine platinum complex mammary antitumor estrogenic mammary cancer inhibitor phenylethyleneamine platinum complex | ||||
| Dewey Decimal Classification: | 500 Science > 540 Chemistry & allied sciences | ||||
| Status: | Published | ||||
| Refereed: | Yes, this version has been refereed | ||||
| Created at the University of Regensburg: | Yes | ||||
| Item ID: | 17706 |
Abstract
[1,2-Bis(4-methoxy/4-hydroxyphenyl)ethylenediamine]dichloroplatinum-(II) complexes were tested on the MDA-MB 231 breast cancer cell line, the lymphocytic leukemia P388, and the estrogen receptor-pos. and -neg. MXT mammary carcinoma of the mouse (MXT,ER(+)-MC, MXT,ER(-)-MC). The comparison of the effects of methoxy-substituted complexes with those of the resp. hydroxy-substituted ones shows that a ...
Abstract
[1,2-Bis(4-methoxy/4-hydroxyphenyl)ethylenediamine]dichloroplatinum-(II) complexes were tested on the MDA-MB 231 breast cancer cell line, the lymphocytic leukemia P388, and the estrogen receptor-pos. and -neg. MXT mammary carcinoma of the mouse (MXT,ER(+)-MC, MXT,ER(-)-MC). The comparison of the effects of methoxy-substituted complexes with those of the resp. hydroxy-substituted ones shows that a redn. of estrogenic effects as well as a total loss of the mammary tumor-inhibiting activity takes place on methylation of the 4-OH group. The exchange of the 2,6-standing chlorine atoms by Me groups led to a non-estrogenic compd. which was highly effective against MXT,ER(+)-MC cells and which also proved to be cytotoxic against ER(-)-tumors such as MXT,ER(-)-MC and the P 388 leukemia.
Metadata last modified: 24 May 2018 12:18
Owner only: item control page
Altmetric